Figures & data
Table 1. Grade 3 or 4 adverse events included in the study*.
Figure 1. Patient selection—Patients with metastatic renal cell carcinoma (RCC) in the SEER-Medicare Database.Citation1 For Medicare Part A and B during a 12-month period prior to diagnosis date.Citation2 Subsequent diagnosis records dated prior to 2007.
Table 2. Characteristics of patients with metastatic renal cell carcinoma, by evidence of treatment-related adverse events (n = 881).
Table 3. Incidence of selected treatment-related adverse events among patients with metastatic renal cell carcinoma, by time since index date (n = 881)*.
Table 4. Mean total cost of medical-care services (excluding cost of targeted therapies) during 30-day post-event period* among patients with metastatic renal cell carcinoma (n = 881).
Table 5. Estimated increase in mean total cost of medical-care services (excluding cost of targeted therapies) associated with evidence of treatment-related adverse events during 30-day post-event period* in patients with metastatic renal cell carcinoma (estimates adjusted for differences in baseline characteristics) (n = 881).